Form 8-K

8-K — MIRA PHARMACEUTICALS, INC.

Accession: 0001493152-26-030033

Filed: 2026-06-25

Period: 2026-06-25

CIK: 0001904286

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001904286

2026-06-25

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): June 25, 2026

MIRA

PHARMACEUTICALS, INC.

(Exact

Name of Registrant as Specified in its Charter)

Florida

001-41765

85-3354547

(State

or Other Jurisdiction

(Commission

(IRS

Employer

Incorporation)

File

Number)

Identification

No.)

1200

Brickell Avenue, Suite 1950 #1183

Miami,

Florida 33131

(Address

of Principal Executive Offices)

Registrant’s

telephone number, including area code: (786) 432-9792

Not

Applicable

(Former

Name or Former Address, if Changed Since Last Report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, $0.0001 par value per share

MIRA

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation FD Disclosure.

June 25, 2026, MIRA Pharmaceuticals, Inc. (the “Company”) issued a press release reporting new preclinical data demonstrating

Mira-55’s differentiated mechanism of action and anxiolytic activity relative to THC. Mira-55 is the Company’s cannabinoid

analog in development for chronic inflammatory pain, designed to act on the same cannabinoid receptors as compounds found in cannabis,

including THC, without carrying THC’s known liabilities, such as psychoactivity, and central nervous system side effects.

Using

standard preclinical models that researchers use to characterize THC-like compounds, the data showed that Mira-55 did not produce the

locomotor suppression or catalepsy associated with THC. Mira-55 produced a modest reduction in body temperature, but unlike the corresponding

THC effect, this was not reversed by rimonabant, a CB1 receptor antagonist, suggesting a mechanism distinct from classical CB1 agonism.

In a separate assay, Mira-55 demonstrated anxiolytic activity, in contrast to anxiogenic activity observed with rimonabant.

The

Company believes these findings, together with preclinical data reported in March 2026, support a pharmacological profile for Mira-55

that is differentiated from THC. These findings are based on preclinical pharmacology studies, and additional research will be required

to further characterize Mira-55’s receptor-level activity as the Company advances its IND-enabling program. A copy of the press

release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The

information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of

Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities

of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the

Exchange Act, except as expressly set forth by specific reference in such filing.

Item

9.01 Financial Statements and Other Exhibits.

(d)

Exhibits.

Exhibit

No.

Description

99.1

Press Release of MIRA Pharmaceuticals, Inc., dated June 25, 2026

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

MIRA PHARMACEUTICALS, INC.

Dated:

June 25, 2026

By:

/s/

Erez Aminov

Name:

Erez

Aminov

Title:

Chief

Executive Officer

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

MIRA

Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55’s Differentiated Mechanism of Action and Anxiolytic Activity

Relative to THC

Data

show Mira-55 does not produce the central nervous system effects associated with THC and acts through a distinct pharmacological mechanism,

while demonstrating anxiolytic activity, which THC does not produce, supporting continued development for chronic inflammatory pain

MIAMI,

FLORIDA / ACCESS Newswire / June 25, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (“MIRA” or the “Company”),

a clinical-stage pharmaceutical company developing novel therapies for neurologic, neuropsychiatric, and metabolic disorders, today announced

new preclinical pharmacology data on Mira-55, the Company’s cannabinoid analog in development for chronic inflammatory pain. Mira-55

is designed to act on the same cannabinoid receptors as compounds found in cannabis, including THC. A central pharmacological question

for the program is whether Mira-55 can deliver therapeutic activity through that receptor system without carrying THC’s known liabilities,

including psychoactivity and central nervous system side effects. This new study addresses that question directly.

Using

a standard test researchers rely on to characterize THC-like compounds, Mira-55 showed a pharmacological profile that sets it apart from

THC, including a meaningful anxiolytic effect that THC does not produce.

These

findings build on data MIRA reported in March 2026, which showed Mira-55 did not produce THC-like side effects and demonstrated anxiety-reducing

activity in animal testing, in contrast to rimonabant, a drug that blocks the same receptor THC acts on. Together, the two studies form

a consistent picture: Mira-55 engages the cannabinoid system differently than THC does, and that difference shows up at both the behavioral

and mechanistic levels.

Study

Overview and Key Findings

Researchers

tested THC and Mira-55, along with rimonabant’s ability to reverse their effects, in the same study using three standard measures

scientists use to characterize THC-like activity: body temperature, movement, and muscle rigidity (Catalepsy). They also tested for anxiety-like

behavior.

● THC

showed the classic pattern of a THC-like compound. It lowered body temperature, slowed

movement, and catalepsy— and all three effects went away when rimonabant was given

alongside it. That is the textbook signature researchers look for to confirm a compound is

acting through the same CB1 pathway as THC.

● Mira-55

showed a different pattern. It produced only one of those three effects, a modest drop

in body temperature, with no effect on movement or rigidity.

● Mira-55’s

mechanism looks different, too. Rimonabant did not block Mira-55’s effect on body

temperature the way it blocked THC’s, suggesting Mira-55 is not working through the

same mechanism as THC, even in the one area where their effects briefly overlap.

● Mira-55

produced a meaningful effect; THC did not: it reduced anxiety-like behavior. Rimonabant

made animals more anxious in this test; Mira-55 made them less anxious — consistent

with what MIRA reported in March, and a distinguishing feature of Mira-55’s profile

rather than simply an absence of THC-like effects.

Why

This Matters

Taken

together, these results support a differentiated pharmacological and mechanistic profile for Mira-55 relative to THC. Mira-55 did not

reproduce THC’s full behavioral pattern; the one effect it did show was not driven by the same mechanism as THC’s, and it

produced an anxiety-reducing effect that THC does not. That combination — a distinct mechanism plus a differentiated, favorable

behavioral effect — is the more complete picture MIRA believes this data supports, beyond simply showing what Mira-55 does not

do.

Integrated

Preclinical Profile

This

mechanistic data adds to a growing body of preclinical evidence for Mira-55:

● Delivered

morphine-comparable pain relief in a validated model of inflammatory pain, without opioid-related

risks

● Did

not produce THC-like CNS side effects across a battery of validated behavioral assays

● Demonstrated

anxiety-reducing activity, in contrast to rimonabant

● Now

shown to act through a mechanism distinct from THC, with a meaningful anxiety-reducing effect

THC does not produce

MIRA

believes this combination of pain-relieving efficacy, a clean CNS safety profile, and a differentiated mechanism supports Mira-55’s

continued advancement toward an IND submission for chronic inflammatory pain.

These

findings are based on preclinical, mechanistic pharmacology studies. Additional studies, including further mammalian and translational

work, will be needed to fully define Mira-55’s receptor activity as MIRA advances its IND-enabling program.

IND

Strategy and Market Opportunity

MIRA

is advancing Mira-55 toward IND-enabling studies for chronic inflammatory pain, a large and growing market with significant unmet medical

need. Current treatment options include opioids, which carry risks of dependence, tolerance, and overdose, and NSAIDs, which may cause

gastrointestinal, renal, and cardiovascular adverse effects.

Leadership

Commentary

“Mira-55

keeps showing the same thing from different angles: a real anxiolytic effect, and a mechanism that doesn’t trace back to THC. That

combination is what differentiates this program. It’s also what we’ll keep building on as we advance Mira-55 toward an IND

in chronic inflammatory pain.”

—

Erez Aminov, Chairman and CEO of MIRA

Dr.

Itzchak Angel, Chief Scientific Advisor, added:

“THC

produced the full pattern you’d expect from a classic THC-like compound, and a CB1 blocker reversed every part of it. Mira-55 only

reproduced one piece of that pattern, and the blocker didn’t reverse it, which tells us Mira-55 is interacting with the receptor

differently than THC does. Mira-55 also did something THC didn’t: it reduced anxiety-like behavior, while the CB1-blocker increased

it. Put together, that’s a distinct mechanism paired with a distinct, favorable effect — a meaningfully different pharmacological

profile, not just an absence of THC’s downsides.”

About

Mira-55

is a next-generation cannabinoid analog designed to modulate cannabinoid receptor activity, including CB1 and CB2 pathways, while minimizing

CB1-related psychoactivity. Following scientific review, the U.S. Drug Enforcement Administration (DEA) determined that Mira-55 is not

classified as a controlled substance.

About

MIRA Pharmaceuticals, Inc.

MIRA

Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical company focused on the development of novel therapies for neurologic,

neuropsychiatric, and metabolic disorders. Its pipeline includes Mira-55 for inflammatory pain, Ketamir-2 for neuropathic pain, and SKNY-1

targeting obesity and smoking cessation. The Company is headquartered in Miami, Florida.

Cautionary

Note Regarding Forward-Looking Statements

This

press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of

1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,”

“plan,” “can,” “could,” “would,” “may,” “will,” “believe,”

“estimate,” “forecast,” “goal,” “project,” “guidance,” “potential,”

“intend,” “seek,” “target” and other words of similar meaning, although not all forward-looking statements

include these words. Forward-looking statements may include, but are not limited to, statements regarding the development of Ketamir-2;

the planned Phase 2a clinical trial, including its design, objectives, enrollment, timing, initiation and potential outcomes; the potential

efficacy, safety, tolerability and therapeutic benefits of Ketamir-2; the potential advantages of Ketamir-2 compared to existing treatment

options; the potential market opportunity for Ketamir-2; future regulatory interactions; intellectual property protection; strategic

partnership opportunities; and the future development and commercialization of Ketamir-2. These forward-looking statements are based

on current expectations, estimates, forecasts, and projections, as well as management’s beliefs and assumptions, and are subject

to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

These risks and uncertainties include, among others, risks related to preclinical and clinical development, the ability to obtain regulatory

approvals, the outcome of future studies, reliance on third parties, intellectual property protection, financing needs, market conditions,

and the other risks identified under the heading “Risk Factors” contained in the Company’s Annual Report on Form 10-K

and the Company’s other filings with the U.S. Securities and Exchange Commission (“SEC”). Forward-looking statements

contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update or revise such statements,

whether as a result of new information, future events, or otherwise, except as required by applicable law.

caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to

read our filings with the SEC, available at the SEC website and in the “Investors” section of our website at MIRA Investors,

for a discussion of these and other risks and uncertainties.

Contact:

Krystina

Quintana

info@mirapharma.com

(786)

432-9792

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 25, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 25, 2026

Entity File Number

001-41765

Entity Registrant Name

MIRA

PHARMACEUTICALS, INC.

Entity Central Index Key

0001904286

Entity Tax Identification Number

85-3354547

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1200

Brickell Avenue

Entity Address, Address Line Two

Suite 1950 #1183

Entity Address, City or Town

Miami

Entity Address, State or Province

Entity Address, Postal Zip Code

33131

City Area Code

(786)

Local Phone Number

432-9792

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, $0.0001 par value per share

Trading Symbol

MIRA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration